Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Kineta

company

About

Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.50M
Industries
Biotechnology,Medical Device,Therapeutics
Founded date
Jan 1, 2008
Number Of Employee
1 - 10
Operating Status
Active
Stock Symbol
nasdaq:KA
Legal Name
Kineta, Inc.
Also Known As
Kineta One LLC

Kineta is a biotechnology company engaging in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, West Nile virus, and the common cold.

Kineta was founded in 2008 and is based in Seattle, Washington.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
20
$83.22M
Kineta has raised a total of $83.22M in funding over 2 rounds. Their latest funding was raised on Dec 28, 2022 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 28, 2022 Series Unknown $7.50M Detail
Dec 19, 2022 IPO Detail
Jun 1, 2021 Corporate Round $17.39M 1 Cheongbo Industrial Co. (CBI) Detail
May 5, 2020 Series Unknown $5M 1 SCHLAEPFER FAMILY FOUNDATION Detail
Aug 6, 2019 Grant $1.80M 1 Wellcome Trust Detail

Employee Profiles

Number of Employee Profiles
9
Kineta has 9 current employee profiles, including Executive Charles Magness
Executive
Executive
Executive
Executive
Executive

Acquisition

Kineta has acquired 1 organizations. Their most recent acquisition was Kineta (Reverse Merger With Yumanity Therapeutics) on Dec 19, 2022. They acquired Kineta (Reverse Merger With Yumanity Therapeutics) for 0.

Date Company Name
Industry Acquisition Type Price
Biotechnology merge Detail